Ambrx to Start US Clinical Trials of HER2 Cancer Drug

Ambrx, a San Diego-China biopharma, will start US clinical trials of ARX78, an antibody drug conjugate targeting HER2. Earlier this year, Ambrx started an Australia-New Zealand trial of the candidate, and China tests are planned. Ambrx, which out-licensed China rights for ARX78 to Zhejiang Medicine in 2013, expects ARX788 will be more effective for more indications than Roche's Herceptin. In 2015 Ambrx was acquired by a consortium of China companies, including Fosun Pharma and WuXi AppTec plus China equity investors HOPU and Everbright. More details.... Stock Symbols: (SHA: 600216) (SX: ROG) (SHA: 600196; HK: 02196) Share this with colleagues: // //